Research On The Motivation And Financial Performance Of Backdoor Listing In Jialin Pharmaceutical

In recent years,China's economic strength has been increasing,and the living standard of the Chinese people has improved significantly.Due to the aging population,China's demand for medicines has been growing.With the support of national policy,it brings great opportunities and challenges to the pharmaceutical industry.However,the pharmaceutical industry is a high-tech industry,which needs a lot of money to support the expenditure of pharmaceutical research and development and production.Therefore,financing has become the first choice for the development of the pharmaceutical industry.Chinese pharmaceutical companies generally raise funds through listing.Benefiting from the integration and reform dividends of the pharmaceutical industry,the investment and mergers of the biomedical industry have not decreased.The number and scale of mergers and acquisitions have been refreshed frequently.Foreign capital has also been stationed in the field of health.From the time distribution of backdoor listing of pharmaceutical enterprises,in recent years,many pharmaceutical companies have obtained a lot of funds by backdoor listing and entered the capital market.This paper analyses the backdoor listing of Jialin Company,summarizes the backdoor listing mode,compares and evaluates the financial performance before and after the backdoor listing of Jialin Company,and provides reference for future pharmaceutical companies that need to be listed by backdoor listing.To make pharmaceutical companies have guiding significance in the long-term development of capital market.This paper elaborates the theory of backdoor listing,the motivation of backdoor listing,the operation mode of M&A fund and financial performance,and makes an in-depth analysis of the case of backdoor listing of Jialin Pharmaceutical Co.,Ltd.and concretely analyses the motivation of backdoor listing and the financial performance after backdoor listing,and finally draws experience and inspiration.The backdoor listing of Jialin Pharmaceutical Industry is the largest backdoor listing case in the history of Chinese pharmaceutical industry,and its listing is also representative.Through the case study of Jialin Pharmaceutical Industry's successful backdoor listing,it provides a new way to solve the strategic development of private enterprises' financing listing.Compared with debt financing,equity financing is more advantageous in introducingM&A funds to promote the listing of enterprises,which can provide reference for enterprises that need to be listed in the future.